The Alphabet Soup of Biologics: Why Your Antibody Therapy Has a 4-Letter FDA Suffix
By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies
If you’ve paid attention to pharmaceutical commercials in the past few years, you’ve likely noticed a bizarre naming convention. The voiceover might introduce a life-changing monoclonal antibody therapy, but when the generic name flashes on the screen, it looks like a typo: adalimumab-atto, infliximab-dyyb, or trastuzumab-dttb.
Those four lowercase letters dangling at the end of the name aren’t a mistake. As you suspected, they are effectively random by design—but they serve a critical function in the drug development and delivery ecosystem.
As we evaluate emerging drug delivery platforms and biologic formulations at Elixis Biosciences, translating complex regulatory frameworks into actionable science is part of the daily routine. For the general public, however, this FDA naming convention can be deeply confusing. To understand why those four letters exist, we have to look at the fundamental difference between traditional chemical drugs and modern biologics.
The Core Problem: Biologics Are Not "Small Molecules"
For decades, the pharmaceutical industry operated mostly on small molecules—simple, stable chemical compounds like ibuprofen or aspirin. Because their chemical structures are relatively straightforward, a competitor can easily reverse-engineer them once the patent expires to create a generic version that is 100% chemically identical to the original.
Biologics, on the other hand, are massive, highly complex molecules (like the antibodies depicted above) manufactured inside living cells, such as yeast or mammalian cell cultures. Because they are grown rather than synthesized, no two batches are truly identical.
When a patent expires on a biologic, competitors can create a "biosimilar." A biosimilar is highly similar to the reference product and has no clinically meaningful differences in terms of safety and efficacy. However, because it is cultured in a different living cell line and undergoes a different extraction process, it is not an exact 1:1 replica.
The Purpose of the Suffix: Pharmacovigilance
Because biosimilars aren't perfectly identical to the original reference drug, the FDA needed a precise way to track exactly which version of a drug a patient received. This tracking is known as pharmacovigilance.
Imagine a scenario where a rare, unforeseen adverse immune reaction starts occurring in patients taking infliximab. If the original biologic and three different biosimilars were all just prescribed and charted as "infliximab," the FDA and the manufacturers would have a nearly impossible time figuring out if the issue was tied to the original drug, a specific biosimilar, or a contaminated batch from one specific manufacturing facility.
By adding a unique four-letter suffix, the FDA ensures that every single biologic product has a distinct nonproprietary name. If a patient has a reaction to infliximab-dyyb, the adverse event reporting system knows exactly which manufacturer’s product was administered. It prevents inadvertent substitution at the pharmacy level and ensures accurate medical record-keeping.
Are the Letters Actually Random?
Yes, today they are intentionally meaningless. But it wasn't always this way.
When the FDA first started experimenting with this naming convention, the suffixes sometimes carried a hidden meaning. For instance, the very first approved biosimilar, filgrastim-sndz, used the suffix "-sndz" as a clear nod to its manufacturer, Sandoz.
However, the FDA soon realized that allowing meaningful suffixes could create unfair marketing advantages or imply that one biosimilar was somehow superior to another. In 2017, the FDA finalized its guidance to level the playing field, stipulating that all proposed suffixes must follow strict, randomized rules:
Four lowercase letters, of which at least three must be distinct.
Devoid of meaning (no hidden acronyms or company abbreviations).
Nonproprietary and free of legal barriers.
Attached with a hyphen to the core name.
This rule change ensured that the suffixes serve solely as a barcode for safety tracking, rather than a branding opportunity.
The Translation Takeaway
Whether we are engineering non-invasive delivery systems or evaluating the physical pharmacy mechanics of a new monoclonal antibody, regulatory foresight is just as important as the formulation itself. The FDA's four-letter suffix is a perfect example of this—a regulatory safeguard engineered specifically for the complexities of modern biologically inspired medicine.
So the next time you see a jumble of letters like -bmez or -axxq at the end of a drug name, you’ll know it’s not a mistake. It is a highly deliberate tracking mechanism designed to keep patients safe as the next generation of therapeutics scales up.
